封面
市場調查報告書
商品編碼
707232

全球重組DNA(rDNA)技術市場:成長、趨勢、預測

Recombinant DNA (rDNA) Technology Market - Growth, Trends, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球重組DNA(rDNA)技術市場相關調查分析,市場概要,各市場區隔、各地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析

第5章 市場區隔

  • 各產品
    • 醫藥品
    • 醫藥品以外
  • 各零件
    • 表現系統
    • 基因複製媒介
  • 各用途
    • 食品、農業
    • 健康、疾病
    • 環境
    • 其他
  • 各終端用戶
    • 生物科技及製藥企業
    • 學術及政府研究機關
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Amgen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd (Genentech Inc.)
    • GenScript
    • Merck KGaA
    • New England Biolabs
    • Novartis AG
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi

第7章 市場機會、未來趨勢

簡介目錄
Product Code: 62776

Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. Moreover, the treatment strategies are improved by developing diagnostics kits, monitoring devices, and new therapeutic approaches. Additionally, many other industries are benefiting from the research conducted on genetically modified organisms (GMO), such as microorganisms that are considered as clean fuel producers and bio degraders. Genetically modified vaccines are developed for curing various diseases in humans and plants. The recombinant DNA technology created several potential innovation opportunities for developing a wide range of therapeutic products, with immediate effect in medical genetics and biomedicine, by modifying microorganisms, animals, and plants, in order to yield medically useful substances. Therefore, the increasing demand and application of RDT in various sectors are driving the growth of the market studied.

Key Market Trends

The Food and Agriculture segment is Expected to Register the Highest CAGR over the Forecast period

In agriculture, the development of genetically modified crops, in order to improve both yield and resistance to pests or herbicides, is gaining a high degree of public acceptance. The genetically modified tomato, CGN-89564-2, was the first commercially grown, genetically engineered crop product to be granted a license for human consumption. Additionally, DNA molecular marker technology is important for preservation, identification, evaluation, mining, and innovation of plant germplasm resources. The introduction of a genetically modified fruit paved the way for the use of GMOs in food. Currently, genetic modification is witnessing a widespread adoption. Thus, increasing the application of RDT in agriculture and food is expected to drive the growth of the market studied.

The North American region is Expected to Dominate the Market Over the Forecast Period

The North American region is expected to dominate the market studied over the forecast period. In the North America region, the United States accounts for the largest market share, primarily due to the presence of numerous biopharmaceutical manufacturing companies and the presence of effective regulatory bodies to monitor the various ethical and scientific concerns, pertaining to the use of technology. This is expected to drive the market's growth, especially in the North American region.

Competitive Landscape

The Recombinant DNA (rDNA) Technology market is competitive, with the presence of both major players and small players. In terms of market share, the major players are currently dominating the market. Some of the major market players include GenScript, New England Biolabs, GlaxoSmithKline Plc, Pfizer, and Sanofi, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Genomics
    • 4.2.2 Expansion of Biopharmaceutical Industry
    • 4.2.3 Increasing Demand and Applications of Recombinant/ Genetically Modified Products
  • 4.3 Market Restraints
    • 4.3.1 Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Medical
      • 5.1.1.1 Therapeutic Agent
      • 5.1.1.2 Human Protein
      • 5.1.1.3 Vaccine
    • 5.1.2 Non-medical
      • 5.1.2.1 Biotech Crops
      • 5.1.2.2 Specialty Chemicals
      • 5.1.2.3 Other Non-medical Products
  • 5.2 By Component
    • 5.2.1 Expression System
    • 5.2.2 Cloning Vector
  • 5.3 By Application
    • 5.3.1 Food and Agriculture
    • 5.3.2 Health and Disease
    • 5.3.3 Environment
    • 5.3.4 Other Applications
  • 5.4 By End User
    • 5.4.1 Biotechnology and Pharmaceutical Companies
    • 5.4.2 Academic and Government Research Institutes
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 Eli Lilly and Company
    • 6.1.3 F. Hoffmann-La Roche Ltd (Genentech Inc.)
    • 6.1.4 GenScript
    • 6.1.5 Merck KGaA
    • 6.1.6 New England Biolabs
    • 6.1.7 Novartis AG
    • 6.1.8 Novo Nordisk A/S
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Sanofi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS